Steve Scala is ranked #1006 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Steve Scala (TD Cowen) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Steve Scala's stock ratings?

About 43% of Steve's ratings were profitable over a one-year hold, with an average return of +6.6% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Steve Scala

Steve Scala

TD Cowen

Wall Street Analyst

★★★☆☆

#1006

on 13Foresight · ranked by our own returns

43%

Success Rate

+6.6%

Average Return

10 of 23 calls profitable · -62.0% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 43% of Steve Scala's ratings turned a profit when each position was held for 1 year — averaging +6.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

25 Buy 40 Hold 0 Sell

Steve's Stock Coverage 27 ratings · 2026-06-23

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
ELAN Elanco Animal Health	Jun 18, 2026	BUY	Strong Buy +24.6% avg upside 18 analysts	$32.00 32.13% Upside	+0.0%
NVS Novartis	Jun 11, 2026	HOLD	Hold -8.2% avg upside 24 analysts	$180.00 22.30% Upside	-4.2%
GSK GlaxoSmithKline	Jun 11, 2026	HOLD	Hold -14.2% avg upside 19 analysts	$70.00 38.16% Upside	-4.0%
ZTS Zoetis	May 07, 2026	BUY	Buy +75.3% avg upside 22 analysts	$150.00 90.62% Upside	-12.2%
PFE Pfizer	May 06, 2026	HOLD	Buy +34.7% avg upside 45 analysts	$30.00 19.08% Upside	-3.9%
NVAX Novavax	May 06, 2026	HOLD	Hold +155.2% avg upside 20 analysts	$9.00 1.40% Downside	-2.5%
GB:AZN AstraZeneca	Apr 30, 2026	BUY	Strong Buy +11.7% avg upside 26 analysts	—	·
RHHBY Roche Holding	Apr 23, 2026	HOLD	Buy +0.7% avg upside 14 analysts	$67.00 34.74% Upside	-0.8%
SNY Sanofi	Apr 23, 2026	HOLD	Strong Buy +76.3% avg upside 20 analysts	$57.00 34.57% Upside	-5.9%
LLY Eli Lilly & Co	Apr 02, 2026	BUY	Buy -10.5% avg upside 47 analysts	$1250.00 13.85% Upside	+18.0%
MRK Merck & Company	Mar 30, 2026	HOLD	Strong Buy +9.7% avg upside 43 analysts	$137.00 20.34% Upside	-3.6%
ABBV AbbVie	Feb 04, 2026	BUY	Buy -2.2% avg upside 43 analysts	$280.00 29.32% Upside	+5.2%
BMY Bristol-Myers Squibb	Jul 31, 2025	HOLD	Buy +8.2% avg upside 42 analysts	$54.00 0.05% Upside	+29.2%
OGN Organon	Apr 22, 2025	HOLD	Sell +10.8% avg upside 9 analysts	$15.00 11.77% Upside	-17.9%
TSE:BHC Bausch Health Companies	Feb 21, 2025	HOLD	Buy +806.7% avg upside 29 analysts	$17.00 158.78% Upside	·
RPRX Royalty Pharma	Dec 24, 2024	BUY	Strong Buy +3.4% avg upside 15 analysts	$42.00 20.75% Downside	+59.5%
ANTX AN2 Therapeutics, Inc.	Nov 18, 2024	HOLD	Buy +64.9% avg upside 7 analysts	—	+12.0%
SPRO Spero Therapeutics	Nov 18, 2024	HOLD	Buy +516.6% avg upside 12 analysts	—	+116.7%
CH:NOVN Novartis AG	Nov 11, 2024	HOLD	Buy -10.8% avg upside 30 analysts	$109.47 7.58% Downside	·
NVO Novo Nordisk	Apr 30, 2024	BUY	Hold +158.8% avg upside 26 analysts	$155.00 258.95% Upside	-47.2%
GB:0QIU Novo Nordisk	Mar 11, 2024	BUY	Hold +40.1% avg upside 28 analysts	$1054.00 259.32% Upside	·
GB:GSK GlaxoSmithKline	Nov 30, 2023	HOLD	Hold -2.6% avg upside 25 analysts	$1790.00 6.55% Downside	·
CH:ROP Roche Holding AG	Nov 14, 2022	HOLD	Strong Buy +3.5% avg upside 23 analysts	$367.00 15.25% Upside	·
FR:SAN Sanofi	Jul 21, 2021	HOLD	Strong Buy +35.8% avg upside 30 analysts	$98.00 36.42% Upside	·
ABUS Arbutus Biopharma	Jun 24, 2021	BUY	Strong Buy +93.7% avg upside 15 analysts	—	-13.7%
DE:MRK Merck KGaA	Dec 10, 2018	HOLD	Strong Buy +2.1% avg upside 32 analysts	$74.97 43.86% Downside	·
AMGN Amgen	Oct 03, 2017	BUY	Buy -12.8% avg upside 57 analysts	$209.00 38.18% Downside	+13.7%

🔒 22 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Steve Scala — Frequently Asked Questions

How accurate are Steve Scala's stock ratings?

Based on the calls 13Foresight could measure, about 43% of Steve's ratings were profitable over a one-year hold, with an average return of +6.6% per rating, or -62.0% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Steve ranked on 13Foresight?

Steve Scala is currently ranked #1006 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Steve cover?

Steve most recently has ratings on ELAN, NVS, GSK, ZTS, PFE, NVAX, GB:AZN, RHHBY, SNY, LLY, MRK, ABBV and 15 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!